Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060398 · ClinicalTrials.gov registry record · Phase 3
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
A Phase 3 study of Prostate Cancer and Fatigue, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
- 20
- Study locations
NCT00060398: Completed Phase 3 study of Prostate Cancer and Fatigue, sponsored by Eastern Cooperative Oncology Group.
NCT00060398 is a Phase 3 study of Prostate Cancer and Fatigue that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 282 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060398, a Phase 3 study of Prostate Cancer and Fatigue, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in treating anemia-related fatigue in patients with prostate cancer that is refractory to treatment with hormone therapy.
Conditions Studied
Interventions
- DRUG dexamethasone
- BIOLOGICAL epoetin alfa
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- Porter Adventist Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- St. Joseph Hospital - Denver
- Rose Medical Center - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
- Swedish Medical Center - Englewood
- Sky Ridge Medical Center - Lone Tree
- Hope Cancer Care Center at Longmont United Hospital - Longmont
- St. Mary-Corwin Regional Medical Center - Pueblo
- North Suburban Medical Center - Thornton
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- Hematology and Oncology Associates - Chicago
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur
California
- Memorial Medical Center Cancer Services - Modesto
Florida
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2004-09-29 |
| Phase | Phase 3 |
What the finished NCT00060398 record still lists
NCT00060398 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (54% lower).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which dexamethasone is the first listed.
NCT00060398 names 20 study sites across 5 states, led by Colorado, Illinois, Georgia.
Frequently Asked Questions
What is clinical trial NCT00060398 about?
NCT00060398 is a clinical study titled "Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer". RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating a...
What is the current status of trial NCT00060398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2004-09-29.
What conditions does trial NCT00060398 study?
This clinical trial studies the following conditions: Prostate Cancer, Fatigue, Anemia.
What interventions are being tested in trial NCT00060398?
The interventions under investigation include: dexamethasone (DRUG), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00060398?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00060398 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00060398's enrollment target sits among peer trials
282 174th of 735 higher than 562 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI